The Colorado State Legislature has introduced Senate Bill 71, aimed at safeguarding the integrity of the 340B drug pricing program, which provides discounted medications to eligible healthcare providers. Introduced on March 25, 2025, the bill seeks to prevent manufacturers, wholesalers, and other entities from imposing restrictions on the acquisition and delivery of 340B drugs to covered entities, including hospitals and contracted pharmacies.

Key provisions of Senate Bill 71 include prohibiting any entity from denying or limiting access to 340B drugs unless explicitly allowed by federal law. Additionally, the bill restricts manufacturers from requiring covered entities to submit health information or data unrelated to federal health care claims, unless such data is voluntarily provided or mandated by federal regulations. Violations of these provisions would be classified as unfair or deceptive trade practices under the Colorado Consumer Protection Act, allowing for enforcement by the state attorney general and potential penalties for violators.

The bill has sparked notable discussions among stakeholders, particularly regarding its implications for pharmaceutical companies and healthcare providers. Proponents argue that it will enhance access to affordable medications for vulnerable populations, while opponents express concerns about potential impacts on drug pricing and the pharmaceutical supply chain.

Furthermore, the legislation mandates that hospitals participating in the 340B program publicly disclose the financial benefits they receive from discounted pharmaceuticals and how these savings are utilized. This transparency measure aims to ensure accountability and foster public trust in the program.

As the bill progresses through the legislative process, its potential economic and social implications are significant. Experts suggest that if enacted, Senate Bill 71 could strengthen the 340B program, ultimately benefiting low-income patients who rely on affordable medications. However, the ongoing debates surrounding the bill highlight the complexities of balancing pharmaceutical industry interests with public health needs.

The next steps for Senate Bill 71 will involve further discussions and potential amendments as it moves through the legislative chambers, with stakeholders closely monitoring its impact on Colorado's healthcare landscape.